866-997-4948(US-Canada Toll Free)

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Jun 2017

Category :

Pharmaceutical

No. of Pages : 95 Pages

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H1 2017

Summary

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Tyrosine-protein kinase JAK3 is an enzyme encoded by the JAK3 gene. It is involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. It plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins.

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) pipeline Target constitutes close to 25 molecules. Out of which approximately 25 molecules are developed by Companies.The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 3, 12 and 5 respectively. Report covers products from therapy areas Immunology, Dermatology, Gastrointestinal, Oncology, Musculoskeletal Disorders, Ophthalmology and Respiratory which include indications Rheumatoid Arthritis, Ulcerative Colitis, Alopecia, Atopic Dermatitis, Autoimmune Disorders, Psoriasis, Diffuse Large B-Cell Lymphoma, Inflammation, Vitiligo, Allergic Conjunctivitis, Androgenic Alopecia, Asthma, Auto Inflammatory Disease, B-Cell Non-Hodgkin Lymphoma, Cachexia, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Lymphocytic Leukemia (CLL), Cutaneous T-Cell Lymphoma, Dermatitis, Dermatomyositis, Follicular Lymphoma, Heart Transplant Rejection, Inflammatory Bowel Disease, Mantle Cell Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Pruritus, Psoriatic Arthritis, Refractory Chronic Lymphocytic Leukemia (CLL), Respiratory Tract Inflammatory Disorders, Sarcopenia, Skin Inflammation, Systemic Lupus Erythematosus, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) and Waldenstrom Macroglobulinemia.

The latest report Tyrosine Protein Kinase JAK3 - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Aclaris Therapeutics Inc
Advinus Therapeutics Ltd
Arrien Pharmaceuticals LLC
Astellas Pharma Inc
Bristol-Myers Squibb Company
Chipscreen Biosciences Ltd
Clevexel Pharma SAS
F. Hoffmann-La Roche Ltd
Japan Tobacco Inc
Merck & Co Inc
MYOS RENS Technology Inc
Pfizer Inc
Portola Pharmaceuticals Inc
Simcere Pharmaceutical Group
Theravance Biopharma Inc
Vectura Group Plc
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Drug Profiles
ARN-4079 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-50001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-50002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-50003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cerdulatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-510 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-944X - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVXL-0074 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JTE-052 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OST-122 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
peficitinib hydrobromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06651600 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PNQ-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK3 for Heart Transplantation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK2 and JAK3 for Oncology and Auto Immune Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK3 for Autoimmune Diseases and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Janus Kinase 3 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNA-125 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-1473 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-3504 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tofacitinib citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VR-588 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association
May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma
May 05, 2017: Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis
May 03, 2017: Pfizer Announces U.S. FDA Filing Acceptance Of Supplemental New Drug Application For Xeljanz (Tofacitinib Citrate) For The Treatment Of Adult Patients With Active Psoriatic Arthritis
May 03, 2017: Phase 3 Octave Studies Of Oral Tofacitinib In Ulcerative Colitis Results Published In The New England Journal Of Medicine
Mar 27, 2017: XELJANZ Receives Marketing Authorisation In The European Union For The Treatment Of Moderate To Severe Active Rheumatoid Arthritis
Mar 15, 2017: Pfizer Announces Approval By The China Food And Drug Administration Of XELJANZ, The First Oral JAK Inhibitor For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis
Mar 13, 2017: European League Against Rheumatism (EULAR) Includes Janus Kinase (JAK) Inhibitors in Updated Recommendations for the Management of RA
Mar 04, 2017: Pfizer to Present Psoriatic Arthritis Data at American Academy of Dermatology Annual Meeting
Feb 17, 2017: Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization
Feb 16, 2017: Pfizer Announces Top-Line Results from the Oral Strategy Trial of XELJANZ (tofacitinib citrate) Compared to Humira (adalimumab)
Feb 13, 2017: Theravance Biopharma to Present Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization
Jan 27, 2017: Pfizer Receives Positive CHMP Opinion in Europe for XELJANZ (tofacitinib citrate) for the Treatment of Moderate to Severe Active Rheumatoid Arthritis
Dec 07, 2016: Aclaris Therapeutics Initiates Phase 1 Clinical Trial for ATI-50001, an Investigational JAK Inhibitor, for the Treatment of Alopecia Totalis and Alopecia Universalis
Nov 28, 2016: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indications, H1 2017
Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by Aclaris Therapeutics Inc, H1 2017
Pipeline by Advinus Therapeutics Ltd, H1 2017
Pipeline by Arrien Pharmaceuticals LLC, H1 2017
Pipeline by Astellas Pharma Inc, H1 2017
Pipeline by Bristol-Myers Squibb Company, H1 2017
Pipeline by Chipscreen Biosciences Ltd, H1 2017
Pipeline by Clevexel Pharma SAS, H1 2017
Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Pipeline by Japan Tobacco Inc, H1 2017
Pipeline by Merck & Co Inc, H1 2017
Pipeline by MYOS RENS Technology Inc, H1 2017
Pipeline by Pfizer Inc, H1 2017
Pipeline by Portola Pharmaceuticals Inc, H1 2017
Pipeline by Simcere Pharmaceutical Group, H1 2017
Pipeline by Theravance Biopharma Inc, H1 2017
Pipeline by Vectura Group Plc, H1 2017
Dormant Products, H1 2017
Dormant Products, H1 2017 (Contd..1), H1 2017
Discontinued Products, H1 2017

List of Figures
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Top 10 Indications, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *